Lyell Immunopharma, Inc. (LYEL) Return on equity 2021–2025
Lyell Immunopharma, Inc. (LYEL) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-110.6%FY2025 · since FY2021: -26.9% → -110.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -110.6% | -21.0 pp |
| FY2024 | -89.6% | -53.8 pp |
| FY2023 | -35.8% | -13.8 pp |
| FY2022 | -22.0% | +4.9 pp |
| FY2021 | -26.9% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More LYEL financial trends
LYEL RevenueLYEL Net incomeLYEL Net marginLYEL Gross profitLYEL Gross marginLYEL Operating incomeLYEL Operating marginLYEL Operating cash flowLYEL Free cash flowLYEL Capital expendituresLYEL Stock buybacksLYEL Dividends paidLYEL Total assetsLYEL Total liabilitiesLYEL Shareholders’ equityLYEL overview →